DDInter581 DDInter927
Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Dolasetron {u} (Compound) resembles {v} (Compound) Hyoscyamine
Dolasetron {u} (Compound) resembles {v} (Compound) Atropine
Dolasetron {u} (Compound) binds {v} (Gene) CYP2D6
Dolasetron {u} (Compound) upregulates {v} (Gene) UBQLN2
Dolasetron {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin 3 Receptor Antagonists
Dolasetron {u} (Compound) causes {v} (Side Effect) Oliguria
Dolasetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Dolasetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rifampicin
Dolasetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxycodone
Dolasetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Donepezil
Dolasetron (Compound) resembles Hyoscyamine (Compound)
Dolasetron (Compound) resembles Atropine (Compound)
Dolasetron (Compound) binds CYP2D6 (Gene)
Dolasetron (Compound) upregulates UBQLN2 (Gene)
Dolasetron (Compound) is included by Serotonin 3 Receptor Antagonists (Pharmacologic Class)
Dolasetron (Compound) causes Oliguria (Side Effect)
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Rifampicin
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Donepezil